OBJECTIVE: Bacterial respiratory tract colonization predisposes critically ill patients to intensive care unit (ICU)-acquired infections. It is unclear to what extent systemic antibiotics affect colonization persistence. Persistence of respiratory tract colonization, and the effects of systemic antibiotics hereon, were determined in a cohort of ICU patients. DESIGN: Clinical and microbiological data were collected from 715 admitted mechanically ventilated ICU patients with bacterial growth documented in respiratory tract samples. First day of colonization, persistence of colonization and antibiotic effects hereon were analyzed for six groups of pathogens: Pseudomonas aeruginosa, Acinetobacter species, Enterobacteriaceae, Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae. Systemic antibiotics were grouped into 'effective' and 'ineffective' antibiotics, based on in-vitro susceptibility data for the relevant bacteria. The effects of antibiotics were quantified as relative risk (RR) of bacterial persistence in the absence of effective antibiotics. MEASUREMENTS AND RESULTS: Persistence of colonization differed significantly between pathogens, ranging from 4 days (median) for H. influenzae and Strep. pneumoniae to 8 days for P. aeruginosa. Systemic antibiotics were administered on 7,102 (61%) of patient days. Antibiotic use was associated with non-persistence for all pathogens, except Acinetobacter species and P. aeruginosa. RR for non-persistence (as compared to ineffective or no antibiotics) ranged from 3.1 (95% CI 1.4-6.6) for H. influenzae to 0.5 (0.3-1.0) for Acinetobacter species. CONCLUSIONS: In mechanically ventilated patients, persistence dynamics of bacterial respiratory tract colonization, and the effects of (in-vitro) effective antibiotics hereon, are pathogen-specific.
OBJECTIVE: Bacterial respiratory tract colonization predisposes critically illpatients to intensive care unit (ICU)-acquired infections. It is unclear to what extent systemic antibiotics affect colonization persistence. Persistence of respiratory tract colonization, and the effects of systemic antibiotics hereon, were determined in a cohort of ICU patients. DESIGN: Clinical and microbiological data were collected from 715 admitted mechanically ventilated ICU patients with bacterial growth documented in respiratory tract samples. First day of colonization, persistence of colonization and antibiotic effects hereon were analyzed for six groups of pathogens: Pseudomonas aeruginosa, Acinetobacter species, Enterobacteriaceae, Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae. Systemic antibiotics were grouped into 'effective' and 'ineffective' antibiotics, based on in-vitro susceptibility data for the relevant bacteria. The effects of antibiotics were quantified as relative risk (RR) of bacterial persistence in the absence of effective antibiotics. MEASUREMENTS AND RESULTS: Persistence of colonization differed significantly between pathogens, ranging from 4 days (median) for H. influenzae and Strep. pneumoniae to 8 days for P. aeruginosa. Systemic antibiotics were administered on 7,102 (61%) of patient days. Antibiotic use was associated with non-persistence for all pathogens, except Acinetobacter species and P. aeruginosa. RR for non-persistence (as compared to ineffective or no antibiotics) ranged from 3.1 (95% CI 1.4-6.6) for H. influenzae to 0.5 (0.3-1.0) for Acinetobacter species. CONCLUSIONS: In mechanically ventilated patients, persistence dynamics of bacterial respiratory tract colonization, and the effects of (in-vitro) effective antibiotics hereon, are pathogen-specific.
Authors: S Ewig; A Torres; M El-Ebiary; N Fábregas; C Hernández; J González; J M Nicolás; L Soto Journal: Am J Respir Crit Care Med Date: 1999-01 Impact factor: 21.405
Authors: M J Bonten; D C Bergmans; A W Ambergen; P W de Leeuw; S van der Geest; E E Stobberingh; C A Gaillard Journal: Am J Respir Crit Care Med Date: 1996-11 Impact factor: 21.405
Authors: D C Bergmans; M J Bonten; C A Gaillard; F H van Tiel; S van der Geest; P W de Leeuw; E E Stobberingh Journal: J Antimicrob Chemother Date: 1997-04 Impact factor: 5.790
Authors: K M C Verhamme; W De Coster; L De Roo; H De Beenhouwer; G Nollet; J Verbeke; I Demeyer; P Jordens Journal: Infect Control Hosp Epidemiol Date: 2007-02-28 Impact factor: 3.254
Authors: Carolina A M Schurink; Stefan Visscher; Peter J F Lucas; Henk J van Leeuwen; Erik Buskens; Reinier G Hoff; Andy I M Hoepelman; Marc J M Bonten Journal: Intensive Care Med Date: 2007-06-16 Impact factor: 17.440
Authors: Sara Gil-Perotin; Paula Ramirez; Veronica Marti; Jose Miguel Sahuquillo; Eva Gonzalez; Isabel Calleja; Rosario Menendez; Juan Bonastre Journal: Crit Care Date: 2012-05-23 Impact factor: 9.097
Authors: Hulda R Thorarinsdottir; Thomas Kander; Anna Holmberg; Sarunas Petronis; Bengt Klarin Journal: Crit Care Date: 2020-06-29 Impact factor: 9.097
Authors: Neha M Doshi; Charles H Cook; Kari L Mount; Stanislaw P Stawicki; Erin N Frazee; Heather A Personett; Garrett E Schramm; Heather M Arnold; Claire V Murphy Journal: BMC Anesthesiol Date: 2013-11-25 Impact factor: 2.217
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Johan Groeneveld; Goran Hedenstierna; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Philipp Metnitz; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2008-12-09 Impact factor: 17.440